Approve cancer biosimilars on analytics and pharmacokinetics, no efficacy trials
Copies of biological cancer drugs are still required to run large trials that rarely change the answer. Dropping them would cut years and tens of millions from each biosimilar.
The MHRA has not required comparative efficacy trials for most biosimilars since 2021, the EMA published a 2025 reflection paper proposing to waive them where analytical and pharmacokinetic similarity are shown, and FDA has signalled the same direction. Comparative efficacy trials for oncology monoclonal antibodies (trastuzumab, bevacizumab, rituximab, and soon pembrolizumab and nivolumab as patents expire around 2028) cost tens of millions and have essentially never overturned a positive analytical package. The proposal is a coordinated ICH-level waiver with a shared analytical similarity standard, so a biosimilar programme runs once for all regions.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Regulatory divergence between regions · Regulatory divergence means a drug approved in one country can take years to reach another, or never arrive.
Pages like this
not linked directly; found by shared links- IdeaBiosimilar-first defaults and payment parity in every cancer day unit
Shares Trastuzumab, Monoclonal antibodies, Prices and value.
- IdeaWHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator
Shares Trastuzumab, Monoclonal antibodies, Regulatory divergence between regions, Prices and value.
- IdeaAutomatic price cuts when a cancer drug's approved indications and volumes expand
Shares Prices and value, Nivolumab, Pembrolizumab.
- IdeaHome infusion and local blood draws for trial drugs after the first cycles
Shares Trastuzumab, Monoclonal antibodies, Nivolumab, Pembrolizumab.
- IdeaPooled procurement and voluntary licensing for essential cancer medicines in low-income countries
Shares Trastuzumab, Prices and value, Pembrolizumab.
- IdeaSubscription pricing for checkpoint inhibitors: fixed national fee, unlimited use
Shares Prices and value, Nivolumab, Pembrolizumab.
- IdeaRestore weight-based dosing and vial sharing for immunotherapy in the label
Shares Prices and value, Nivolumab, Pembrolizumab.
- IdeaPublicly funded trials of lower and less frequent doses of expensive cancer drugs
Shares Prices and value, Nivolumab, Pembrolizumab.